DFTX
Definium Therapeutics, Inc.
DFTX
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon